Lakewood-amedex Biotherapeutics Inc

This management proposal asks shareholders to approve an amendment to the Company’s Articles of Incorporation to increase authorized common shares from 12.5 million to 100 million. Management and the Board argue the increase is prudent to provide flexibility for future capital raising, strategic transactions, and equity-based incentives without needing to call a special shareholder meeting for additional authorization. The Board states there are no current plans, commitments, or understandings to issue the newly authorized shares, but notes the additional capacity would permit prompt issuance if opportunities arise. The filing of the Amended Articles with the Nevada Secretary of State would effectuate the increase if approved. The Board also addresses potential anti-takeover concerns, disclaiming any intent to use the increased authorization as an anti-takeover device but acknowledging the theoretical possibility that additional authorized-but-unissued shares could be used in a manner that makes a takeover more difficult. The recommendation rationale centers on administrative and strategic flexibility, cost and timing efficiencies, and the need to have shares available for employee and contractor incentives and to support transactions. From a governance perspective, shareholders will see dilution risk as a primary countervailing factor; management notes that any issuance that legally requires shareholder approval would still be submitted for a vote. Analytically, approval increases the Company’s ability to pursue acquisitions and equity financings quickly but could materially dilute current holders if used extensively; investors should weigh the tradeoff between flexibility for growth and potential dilution and seek disclosure on any near-term planned issuances after approval.

This management proposal asks shareholders to authorize the Board to effect one or more reverse stock splits, at a ratio determined by the Board up to a cumulative one-for-twenty, without further shareholder approval and only if the Board later elects to do so prior to September 22, 2027. Management frames the authority as a tool to maintain Nasdaq Capital Market listing compliance (notably the $1.00 minimum bid price requirement) and to potentially improve marketability and liquidity by increasing the per-share price. The Board emphasizes that implementation is discretionary and will consider multiple factors—historical and prevailing trading price and volume, reserve needs for convertible securities, financing prospects, and market conditions—before deciding whether and at what ratio to act. The company notes that a reverse split would not change shareholders’ proportionate ownership (except for fractional-share rounding), but it would create additional authorized but unissued shares and thus increase potential future dilution. Risks are acknowledged: a reverse split may fail to achieve sustained price improvement and could reduce liquidity by decreasing the number of outstanding shares; other Nasdaq listing requirements beyond price may still lead to delisting. The Board also reserves the right to abandon any split even if authorized, and management highlights the planned rounding-up treatment for fractional shares. The proposal balances the benefit of tactical flexibility to preserve listing status against dilution and liquidity tradeoffs; investors should monitor any proposed ratio, timing, and the Company’s rationale if the Board later elects to effect a split.

This management proposal seeks shareholder approval to amend the Company’s 2020 Equity Incentive Plan by increasing the total number of shares authorized for awards from 183,505 to 400,000, an increase of 216,495 shares. Management’s stated rationale is to preserve the Company’s ability to grant equity-based incentives necessary to recruit, retain and motivate employees, directors and service providers and to align their interests with shareholders, particularly given a small employee base and the Company’s growth objectives. The Board approved the amendment subject to stockholder consent and notes that without approval the plan remains in effect but could lack sufficient shares for future grants, potentially forcing the Company to rely more heavily on cash compensation or other alternatives. The plan permits options and restricted stock and is administered with broad administrator discretion, including making equitable adjustments for corporate events; approval therefore increases the pool available for both incentive and nonqualified options and restricted stock awards. From a governance standpoint, investors should account for dilution risk from additional potential issuances, the absence of precise allocation commitments, and potential related-party benefits because directors and executives are eligible to receive awards. The Board emphasizes that new grants are discretionary and will be based on business needs; sophisticated investors should seek post-approval disclosure on intended grant programs, expected dilution over time, and metrics tying awards to performance to assess the long-term shareholder impact.